BIOMAT Database Logo BIOMAT Database Logo

Prediction of the optimum clinical dosing schedule for menogaril from results with tumor-bearing mice. 1996

M Yoshida, and T Kobunai, and K Nakano, and H Saito, and T Toko, and S Takeda, and N Unemi
Anticancer and Antimicrobials Research Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan.

Menogaril is an antitumor agent active after oral administration, and unlike other anthracyclines, extravasation cannot occur. When the IC90 values of menogaril were plotted versus exposure time on a double-logarithmic scale, the regression lines had slopes between -0.64 and -0.80. These results showed that the mode of action of menogaril was type lb, dependent on the area under the curve (AUC) of concentration versus time, like Adriamycin. In calculations that simulated pharmacokinetic findings if administration were for three consecutive days (the single dose given was 79 mg/kg) or on days 1 and 8 (the single dose was 238 mg/kg), the peak tumor concentration of menogaril was 1870 and 2985 ng/g and the AUC was 68,363 and 89,352 ng/g hour, respectively. Of the dosing schedules tried, these two dosing schedules were the optimum, with satisfactory antitumor activity against mouse solid tumor Colon 26 and with a wide range of effective dose concentrations. Since menogaril was AUC-dependent, it was possible to predict antitumor activity and to choose optimum dosing schedules on the basis of cell-kill kinetic and pharmacokinetic information.

UI MeSH Term Description Entries
D008297 Male Males
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured

Related Publications

M Yoshida, and T Kobunai, and K Nakano, and H Saito, and T Toko, and S Takeda, and N Unemi
Optimizing the dosing schedule of l-asparaginase improves its anti-tumor activity in breast tumor-bearing mice.
April 2018, Journal of pharmacological sciences,
M Yoshida, and T Kobunai, and K Nakano, and H Saito, and T Toko, and S Takeda, and N Unemi
[Importance of measuring blood level of lamotrigine for optimum dosing schedule].
September 2014, No to hattatsu = Brain and development,
M Yoshida, and T Kobunai, and K Nakano, and H Saito, and T Toko, and S Takeda, and N Unemi
Comparison of urine proteomes from tumor-bearing mice with those from tumor-resected mice.
January 2023, PeerJ,
M Yoshida, and T Kobunai, and K Nakano, and H Saito, and T Toko, and S Takeda, and N Unemi
Antibiotic dosing in obesity: the search for optimum dosing strategies.
December 2014, Clinical obesity,
M Yoshida, and T Kobunai, and K Nakano, and H Saito, and T Toko, and S Takeda, and N Unemi
Transplantation of tumor by blood from tumor-bearing mice.
September 1969, The Kumamoto medical journal,
M Yoshida, and T Kobunai, and K Nakano, and H Saito, and T Toko, and S Takeda, and N Unemi
[Optimization of streptozotocin dosing for establishing tumor-bearing diabetic mouse models].
June 2014, Nan fang yi ke da xue xue bao = Journal of Southern Medical University,
M Yoshida, and T Kobunai, and K Nakano, and H Saito, and T Toko, and S Takeda, and N Unemi
Isozymes in the liver from mice given hepatocarcinogen and from tumor-bearing mice.
August 1971, Gan,
M Yoshida, and T Kobunai, and K Nakano, and H Saito, and T Toko, and S Takeda, and N Unemi
Soluble suppressor factor from the spleens of tumor-bearing mice.
July 1978, Cancer research,
M Yoshida, and T Kobunai, and K Nakano, and H Saito, and T Toko, and S Takeda, and N Unemi
Tumor-associated blocking factors: isolation from sera of tumor-bearing mice.
March 1976, Journal of immunology (Baltimore, Md. : 1950),
M Yoshida, and T Kobunai, and K Nakano, and H Saito, and T Toko, and S Takeda, and N Unemi
Maximum-tolerated dose, optimum biologic dose, or optimum clinical value: dosing determination of cancer therapies.
August 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!